Key result
Metabolomic profiling identified 44 significantly altered metabolites that distinguished single ventricle patients with heart failure from those without (AUC 0.885) and healthy controls (AUC 0.995).
Why the study?
Children and young adults with single ventricle heart disease frequently develop intractable heart failure, but the underlying molecular and biochemical mechanisms are poorly understood and predictive biomarkers are urgently needed.
Does metabolomic profiling identify circulating biomarkers associated with heart failure in young single ventricle patients?
Cross-Sectional (n=26)
No
Does metabolomic profiling identify circulating biomarkers associated with heart failure in young single ventricle patients?
Metabolomic profiling identified 44 circulating metabolites that can distinguish between single ventricle patients with and without heart failure, providing potential biomarkers for disease progression.
May identify HF biomarkers in young SV patients; hypothesis-generating and requires prospective validation.
BACKGROUND: Children and young adults with single ventricle (SV) heart disease frequently develop heart failure (HF) that is intractable and difficult to treat. Our understanding of the molecular and biochemical reasons underlying this is imperfect. Thus, there is an urgent need for biomarkers that predict outcome and provide a rational basis for treatment, and advance our understanding of the basis of HF. OBJECTIVE: We sought to determine if a metabolomic approach would provide biochemical signatures of HF in SV children and young adults. If significant, these analytes might serve as biomarkers to predict outcome and inform on the biological mechanism(s) of HF. METHODS: We applied a multi-platform metabolomics approach composed of mass spectrometry (MS) and nuclear magnetic resonance (NMR) which yielded 495 and 26 metabolite measurements respectively. The plasma samples came from a cross-sectional set of young SV subjects, ages 2-19 years with ten control (Con) subjects and 16 SV subjects. Of the SV subjects, nine were diagnosed as congestive HF (SVHF), and 7 were not in HF. Metabolomic data were correlated with clinical status to determine if there was a signature associated with HF. RESULTS: There were no differences in age, height, weight or sex between the 3 cohorts. However, statistical analysis of the metabolomic profiles using ANOVA revealed 44 metabolites with significant differences between cohorts including 41 profiled by MS and 3 by NMR. These metabolites included acylcarnitines, amino acids, and bile acids, which distinguished Con from all SV subjects. Furthermore, metabolite profiles could distinguish between SV and SVHF subjects. CONCLUSION: These are the first data to demonstrate a clear metabolomic signature associated with HF in children and young adults with SV. Larger studies are warranted to determine if these findings are predictive of progression to HF in time to provide intervention.
No takes yet. Share an insight, caveat, or question.
O’Connell et al. (2021) conducted a cross-sectional in Single ventricle heart disease and heart failure (n=26). Single ventricle heart disease with or without heart failure vs. Healthy controls was evaluated on Significantly altered metabolites between cohorts. Metabolomic profiling identified 44 significantly altered metabolites that distinguished single ventricle patients with heart failure from those without (AUC 0.885) and healthy controls (AUC 0.995).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: